Search

HCL BigFix Flaw Allows Privilege Escalation

CERT-Bund published a security advisory regarding a vulnerability in HCL BigFix Service Management (versions prior to 27). The flaw, rated CVSS Base Score 8.3 (high) and CVSS Temporal Score 7.2 (high), allows a remote authenticated attacker to bypass security controls and potentially escalate privileges. The vulnerability affects systems running Linux, UNIX, and Windows. A mitigation is available.

Fagron Compounding Services Vancomycin HCL Class II Recall - Sterility Concerns

Fagron Compounding Services issued a voluntary Class II recall for Vancomycin HCL 1 gram in 0.9% Sodium Chloride Injection USP due to lack of assurance of sterility and a potential defect where the blue Break-Off-Part could detach from the administration port. The recall affects 11,680 bags distributed nationwide across seven lot numbers with expiration dates ranging from May to July 2026.

US12605402B2 Oxidizing Acid Solution Patent Grant

The USPTO granted patent US12605402B2 to APR Applied Pharma Research SA covering methods for treating Epidermolysis Bullosa (EB), EGFR inhibitor-induced skin toxicities, Hailey-Hailey Disease (HHD), Buruli Ulcers, and SARS-CoV-2 infections using topical hypotonic acid oxidizing solutions containing hypochlorous acid (HClO). The patent contains 22 claims and was filed on July 2, 2020 under application number 17597220. This grant confers enforceable intellectual property rights to the assignee but does not itself impose compliance obligations on other market participants.

Amneal Recalls Tramadol HCl Tablets Due to NDSRI Impurity

Amneal Pharmaceuticals LLC has issued a voluntary Class II drug recall for Tramadol Hydrochloride Tablets USP 50mg (500-count bottles) due to detection of N-nitroso-desmethyl-tramadol (NDSRI) impurity exceeding specification limits at the 24-month stability interval. Two lots totaling 29,542 bottles are affected: AM230987 (exp. 05/2026) and AR232387 (exp. 12/2026). Distribution was nationwide within the United States.

HCL BigFix Multiple Vulnerabilities Remote Attack CVSS 5.3

CERT-Bund, the German Federal Computer Emergency Response Team, published security advisory WID-SEC-2026-1186 alerting to multiple vulnerabilities in HCL BigFix Service Management versions prior to 26.0 and 27. The vulnerabilities carry a CVSS Base Score of 5.3 (medium) and Temporal Score of 4.6 (medium), with remote attack confirmed as feasible. An attacker can exploit these flaws to bypass security measures and disclose information. Affected platforms include Linux, UNIX, and Windows. Mitigation measures are available.

Actian Corporation v. Great Western Malting Co. - Copyright Infringement and Breach of Contract

Actian Corporation filed a civil complaint against Great Western Malting Co. in the U.S. District Court for the Northern District of California on April 10, 2026. The complaint alleges copyright infringement and breach of contract. Actian Corporation, a software company owned by HCL Technologies, seeks damages and injunctive relief for unauthorized use of its intellectual property.

Blue Rabbit Veterinary LLC Controlled Substance Importer Application

The DEA published notice that Blue Rabbit Veterinary LLC applied to be registered as an importer of Schedule II controlled substances Etorphine HCL (9059) and Thiafentanil (9729) for sale to veterinarians. The application was filed February 23, 2026, with comments on the registration due May 4, 2026.

HCL America Settles Age and National Origin Discrimination Lawsuit

The EEOC announced that HCL America will pay $495,000 to settle a lawsuit alleging age and national origin discrimination. The case involved claims that the company rejected a 62-year-old Indian job applicant based on discriminatory factors. The settlement includes compensatory damages for the affected individual.

Contract Award: Function Support at Highcliffe Castle

Bournemouth, Christchurch and Poole Council has awarded a contract valued at £180,000 (excluding VAT) to SLICK EVENTS LIMITED for Function Support Services at Highcliffe Castle. The contract is set to begin on April 1, 2026, and will run until March 31, 2028, with potential extensions.

Draft Labeling for Atomoxetine HCL Solution

The FDA has posted draft labeling for Atomoxetine HCL Solution for public comment. This document outlines proposed changes to the drug's labeling, which will impact manufacturers and potentially healthcare providers.

Moxifloxacin ophthalmic solution recall due to assay out of trend

Health Canada issued a Type II recall for pms-MOXIFLOXACIN HCL 0.5% Ophthalmic Solution (DIN 02432218, Lot 240518) distributed nationally by Pharmascience. The recall was triggered because the assay is out of trend for the affected lot. Healthcare providers and consumers should verify if they have the affected product and consult with healthcare professionals before discontinuing use.

Rushcliffe Borough Council EIR Planning Information Not Held

The Information Commissioner's Office issued a Decision Notice finding that Rushcliffe Borough Council correctly applied the Environmental Information Regulations exception at regulation 12(4)(a). The Council stated that requested planning application information was not held, and the Commissioner determined on the balance of probabilities that the information is indeed not held by the Council.

HCL BigFix Platform Multiple Vulnerabilities

CERT-Bund issued a security advisory (WID-SEC-2026-0960) identifying multiple vulnerabilities in HCL BigFix Platform affecting versions prior to 11.0.6. The vulnerabilities carry a CVSS Base Score of 8.8 (high) and a Temporal Score of 7.7 (high). Local attackers can exploit these flaws to bypass security mechanisms and disclose sensitive information. Mitigation measures are available.

USP Notice: Revision to Guaifenesin, Pseudoephedrine HCL, Dextromethorphan Capsules Monograph

The United States Pharmacopeia (USP) has issued a notice of intent to revise the monograph for Guaifenesin, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Capsules. The revision aims to update a cross-reference to an omitted monograph and incorporate the full text of a previously official assay procedure.